Hisense obtains approval to conduct clinical trials of HSK47977 tablets
August 13, 2025
Source: drugdu
106
August 12, Hisense(002653) announced that the company recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving its independently developed innovative drugHSK47977 tablets are undergoing clinical trials. This drug is an oral BCL6 PROTAC small molecule formulation, primarily used to treat non-Hodgkin's lymphoma, and meets the relevant drug registration requirements.
HSK47977 tablets have no clinically active drugs targeting the same target in China, and they hold the potential to become a first-in-class product. The company completed Pre-IND discussions with the FDA in July 2025 and submitted an IND application, with the potential for simultaneous development in China and the US. Preclinical studies have demonstrated potent anti-tumor activity and a favorable safety profile, demonstrating high development potential.
In the first quarter of 2025, Hisense achieved revenue of 892 million yuan and net profit attributable to shareholders of the parent company of 46.61 million yuan.
https://finance.eastmoney.com/a/202508123482166131.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Baiyang Pharmaceuticals and Jeterbeline join hands to expand the human serum albumin market November 5, 2025
- Plans to Advance Multiple Phase III Lung Cancer Phase II Clinical Trials. (This is part of a larger effort to validate the efficacy of PD-L1 ADC.) November 5, 2025
- Baili Tianheng’s HER2 ADC drug T-Bren receives Breakthrough Designation for HER2-positive gastric cancer November 5, 2025
- HP515 Phase II Clinical Trial Completes First Batch of Participant Enrollment November 5, 2025
- FDA Issues Safety Alert for Radiofrequency Microneedling November 5, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
